News and Press Releases
Psyence Group Inc. Enters Into Amalgamation Agreement With Goldcoast Resource Corp.
Psyence Group Inc. has entered into a definitive amalgamation agreement (the “Agreement”) dated November 21, 2025 with GoldCoast Resource Corp. (“GoldCoast”) and Psyence Therapeutics Corp., a wholly owned subsidiary of Psyence (“Psyence Subco”).
Psyence Group Inc. Announces RSU Grants
Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") to certain executives, officers, directors and consultants of the Company pursuant to the Company’s Amended and Restated Restricted Share Unit Plan, of which one third vests six months after the grant date, another one third after twelve months and the remaining balance after eighteen months.
Psyence Group INC. Enters Into A Letter Of Intent To Acquire Goldcoast Resource Corp.
Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the issued and outstanding securities and securities convertible into securities of GoldCoast Resource Corp. (the "Target" or "GoldCoast"), a corporation existing under the laws of Ontario (the "Acquisition").The Acquisition constitutes a "Change of Business" under the Canadian Securities Exchange ("CSE") policies.
Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds
TORONTO, ONTARIO, July 7, 2025 – Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), is pleased to announce that it has successfully closed the second tranche (“Tranche 2”) of its previously announced non‑brokered private placement (the “Offering”), relying on the accredited investor exemption under section 2.3 of National Instrument 45-106 — Prospectus Exemptions.
Psyence Group Inc. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or about July 4, 2025 for the remaining gross proceeds of C$124,000. The Offering was originally announced on June 18, 2025. The net proceeds of the Offering will be used for general working capital purposes.
Psyence Group Inc. Announces Offering of up C$600,000 Non-Brokered Private Placement of Common Shares
Psyence Group Inc are pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.
Psyence Group Announces Share Consolidation
Psyence Group Inc announces that the Company will be consolidating all of its issued and outstanding share capital (the “Common Shares”) on the basis of every fifteen (15) old Common Shares into one (1) new Common Share (the “Share Consolidation”), effective April 23, 2025 with a record date of April 23, 2025 (the “Record Date”).
Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein
Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it has expanded its newly created Scientific Advisory Board (SAB) with the addition of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology.
Psyence Group’s NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB).
News and Press Releases
Psyence In The News
